Keitaro Senoo

Keitaro Senoo

Auto-generated profile, based on publicly available information

Keitaro Senoo

Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Circulation Journal
Verified
Journal Article
Open access
PDF file
KSKeitaro Senoo
Keitaro Senoo
SSShinya Suzuki
Shinya Suzuki
TOTakayuki Otsuka
Takayuki Otsuka
KSKoichi Sagara
Koichi Sagara
SMShunsuke Matsuno
Shunsuke Matsuno
TYTakeshi Yamashita
Takeshi Yamashita
Background: This study investigated the progression of paroxysmal atrial fibrillation (AF) to the persistent form in Japanese asymptomatic AF patients. Methods and Results: Data were derived from a single hospital-based cohort in the Shinken Database 2004–2012 (n=19,994), in which 1,176 patients were diagnosed as having paroxysmal AF. AF progression occurred in 115 patients (6.0%/year) during the mean follow-up period (1,213±905 days). Although patients who were asymptomatic at the initial visit (n=468) had a low-risk profile compared with symptomatic patients, they had greater AF progression at follow-up (unadjusted hazard ratio, 1.611; 95% CI: 1.087–2.389; P=0.018). Absence of symptoms, male sex, and cardiomyopathy were independent predictors for AF progression in the multivariate model. It was noted that asymptomatic patients were less likely to undergo pulmonary vein isolation (PVI). In addition, the interaction term between asymptomatic AF and absence of PVI could be another independent predictor for AF progression. Prognosis was similar between asymptomatic and symptomatic patients with AF. Conclusions: Irrespective of low-risk profile, patients with asymptomatic paroxysmal AF had greater progression of AF compared with symptomatic patients. This paradoxical result appeared to be the result of less intensive clinical management, including invasive rhythm control. (Circ J 2014; 78: 1121–1126)

7 January 2022 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
KSKeitaro Senoo
Keitaro Senoo
TMTomonori Miki
Tomonori Miki
TOTakashi Ohkura
Takashi Ohkura
HIHibiki Iwakoshi
Hibiki Iwakoshi
TNTetsuro Nishimura
Tetsuro Nishimura
SMSatoaki Matoba
Satoaki Matoba
Background: Poor adherence to oral anticoagulation in elderly patients with atrial fibrillation (AF) has been shown to negatively impact health care costs, morbidity, and mortality. Although various methods such as automated reminders, counseling, telephone support, and patient education have been effective in improving medication adherence, the burden on health care providers has been considerable. Recently, an attempt has been made to improve medication adherence without burdening health care providers by using smartphone apps; however, the use of the app for elderly patients with AF is still limited. Objective: The purpose of this study was to determine whether the newly developed smartphone app for patients with AF (the Smart AF), which integrates education, automatic reminder, and patient engagement strategies with a simple user interface, can improve medication adherence in elderly patients with AF. Methods: Patient enrollment was carried out by obtaining informed consent from patients with AF attending Kyoto Prefectural University of Medicine hospital between May 2019 and September 2020. Follow-up was planned at 1, 3, and 6 months after enrollment, and questionnaire reminders were automatically sent to patient apps at designated follow-up time points. A questionnaire-based survey of medication adherence was performed electronically using the self-reported 8-item Morisky Medication Adherence Scale (MMAS-8) as the survey tool. Results: A total of 136 patients with AF were enrolled in this study. During the follow-up period, 112 (82%) patients underwent follow-up at 1 month, 107 (79%) at 3 months, and 96 (71%) at 6 months. The mean age of the enrolled patients was 64.3 years (SD 9.6), and male participants accounted for 79.4% (108/136) of the study population. The mean CHADS2 (congestive heart failure, hypertension, age, diabetes, previous stroke, or transient ischemic attack) score was 1.2, with hypertension being the most common comorbidity. At the time of enrollment, 126 (93%) and 10 (7%) patients were taking direct oral anticoagulants and warfarin, respectively. For medication adherence as measured according to the MMAS-8, MMAS scores at 1 month, 3 months, and 6 months were significantly improved compared with baseline MMAS scores (all P values less than .01). The overall improvement in medication adherence achieved by the 6-month intervention was as follows: 77.8% (14/18) of the patients in the high adherence group (score=8) at baseline remained in the same state, 45.3% (24/53) of the patients in the medium adherence group (score=6 to <8) at baseline moved to the high adherence group, and 72% (18/25) of the patients in the low adherence group (score <6) moved to either the medium or high adherence group. Conclusions: The Smart AF app improved medication adherence among elderly patients with AF. In the realm of medication management, an approach using a mobile health technology that emphasizes education, automatic reminder, and patient engagement may be helpful.

1 January 2012 in Circulation Journal
Verified
Journal Article
Open access
PDF file
KSKeitaro Senoo
Keitaro Senoo
SSShinya Suzuki
Shinya Suzuki
KSKoichi Sagara
Koichi Sagara
TOTakayuki Otsuka
Takayuki Otsuka
SMShunsuke Matsuno
Shunsuke Matsuno
TYTakeshi Yamashita
Takeshi Yamashita
Background: The characteristics and prognosis of patients with first-detected atrial fibrillation (AF) in Japan remain unclear. Methods and Results: First-detected AF patients without structural heart disease (n=289) were reviewed with regard to 2 symptom classifications (CCS-SAF and EHRA). In both classifications, asymptomatic patients comprised ≈40% of the patients, and patients in the most symptomatic class (≈6%) had peculiar characteristics and poor prognosis. In other symptomatic classes, symptoms affected the treatment strategy without a significant difference in the patients' backgrounds and prognosis. Conclusions: This is the first report to describe the distribution, characteristics and outcomes of first-detected AF patients according to symptom classifications. (Circ J 2012; 76: 1020-1023)

1 October 2016 in International Journal of Cardiology
Verified
Journal Article
Open access
KSKeitaro Senoo
Keitaro Senoo
Gregory LipGregory Lip
Gregory Lip
Simple bleeding risk scores have been proposed to predict bleeding events, in patients anticoagulated using non-warfarin anticoagulants. We compared the relative predictive values of two bleeding risk scores, HAS-BLED and ORBIT, in non-warfarin anticoagulated patients with atrial fibrillation (AF). In a post-hoc ancillary analysis of 'clinically relevant bleeding' events amongst 2283 patients in the idraparinux arm in the AMADEUS trial. The two scores performed modestly in predicting both bleeding outcomes, although there was a trend for better HAS-BLED score performance in predicting any clinically relevant bleeding [c-indexes in HAS-BLED vs. ORBIT; 0.61 (95% CI; 0.58-0.64) vs. 0.58 (95% CI; 0.55-0.61); c-index difference=0.03, z-score=1.84, p=0.06)]. Using the HAS-BLED score compared with the ORBIT score correctly and significantly reclassified 15.6% of the population (95% CI: 4.3 to 27.0; p=0.007). Decision curve analyses confirmed the increasing ability to correctly identify patients who would bleed using the HAS-BLED score versus the ORBIT score, over a wide range of thresholds for any clinically relevant bleeding risk predictions. In this comparison of the HAS-BLED and ORBIT scores in a cohort of non-warfarin anticoagulated patients with AF, we show that the HAS-BLED score more accurately predicted any clinically relevant bleeding amongst patients with AF who were anticoagulated with a non-warfarin anticoagulant, when compared with the ORBIT score.

25 September 2013 in Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
KSKeitaro Senoo
Keitaro Senoo
SSShinya Suzuki
Shinya Suzuki
KSKoichi Sagara
Koichi Sagara
TOTakayuki Otsuka
Takayuki Otsuka
SMShunsuke Matsuno
Shunsuke Matsuno
TYTakeshi Yamashita
Takeshi Yamashita

19 January 2023 in IJC Heart & Vasculature
Verified
Journal Article
Open access
KSKeitaro Senoo
Keitaro Senoo
AYArito Yukawa
Arito Yukawa
TOTakashi Ohkura
Takashi Ohkura
HIHibiki Iwakoshi
Hibiki Iwakoshi
TNTetsuro Nishimura
Tetsuro Nishimura
SMSatoaki Matoba
Satoaki Matoba
This multicenter prospective observational study examined the impact of additionally using a home electrocardiograph (ECG) to detect atrial fibrillation (AF) recurrence after ablation. Between May 2019 and December 2020, 128 patients undergoing ablation were enrolled in the study. After performing ablation, they were instructed to measure their ECGs at home using Complete (ECG paired with a blood pressure monitor; Omron Healthcare, Japan) every day and to visit the hospital every 3 months until after 12 months for 24-hour Holter ECG and 12-lead ECG as usual care (UC). After ablation, 94 patients were followed up, and AF recurrence at 12 months was detected more commonly in adjudicators-interpreted Complete (31 [33 %]) than in UC (18 [9 %]) (hazard ratio 1.95, 95 % confidence interval [95 %CI] 1.35-2.81, P < 0.001). In patients with recurrent AF found via both modalities (n = 16), the time to first AF detection by Complete was 40.9 ± 73.9 days faster than that in UC (P = 0.04). Notably, when the adherence to Complete measurement was divided by 80 %, the add-on effect of Complete on the detection of recurrent AF in UC indicated the hazard ratio (HR) of 1.71 (95 %CI 0.92-3.18, P = 0.09) for the low adherence (<80 %) group, but it was significant for the high adherence (≥80 %) group, with HR of 2.19 (95 %CI 1.43-3.36, P < 0.001). Despite a shorter measurement time, Complete detected recurrent AF more frequently and faster compared with UC after AF ablation. A significant adherence-dependent difference of Complete was found in detecting AF recurrence.